Editas Medicine Inc Investor Relations Material

Editas Medicine, a genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company seeks to address the fundamental flaws in existing approaches to genetic and infectious diseases by developing TALEN and CRISPR genome editing systems that function more efficiently than existing technologies. It has invented lymphocyte-directed gene therapy that uses CRISPR/Cas9 technology to manufacture a novel endonuclease. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts